175 related articles for article (PubMed ID: 37259155)
1. ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade.
Ralser DJ; Herr E; de Vos L; Kulcsár Z; Zarbl R; Klümper N; Gielen GH; Maas AP; Hoffmann F; Dietrich J; Kuster P; Mustea A; Glodde N; Kristiansen G; Strieth S; Landsberg J; Dietrich D
Biomark Res; 2023 Jun; 11(1):56. PubMed ID: 37259155
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy.
Niebel D; Fröhlich A; Zarbl R; Fietz S; de Vos L; Vogt TJ; Dietrich J; Sirokay J; Kuster P; Saavedra G; Ramírez Valladolid S; Hoffmann F; Strieth S; Landsberg J; Dietrich D
Clin Epigenetics; 2022 Apr; 14(1):50. PubMed ID: 35410311
[TBL] [Abstract][Full Text] [Related]
4. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
5. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Hoffmann F; Franzen A; de Vos L; Wuest L; Kulcsár Z; Fietz S; Maas AP; Hollick S; Diop MY; Gabrielpillai J; Vogt T; Kuster P; Zarbl R; Dietrich J; Kristiansen G; Brossart P; Landsberg J; Strieth S; Dietrich D
Clin Epigenetics; 2023 Jul; 15(1):112. PubMed ID: 37415208
[TBL] [Abstract][Full Text] [Related]
6. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract][Full Text] [Related]
7. The landscape of
de Vos L; Grünwald I; Bawden EG; Dietrich J; Scheckenbach K; Wiek C; Zarbl R; Bootz F; Landsberg J; Dietrich D
Epigenetics; 2020 Nov; 15(11):1195-1212. PubMed ID: 32281488
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T-cell costimulator as a crucial immune checkpoint molecule.
Chu J; Wu Y; Qu Z; Zhuang J; Liu J; Han S; Wu W; Han S
Cancer Med; 2024 Mar; 13(6):e7097. PubMed ID: 38506253
[TBL] [Abstract][Full Text] [Related]
10. Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.
Holderried TAW; de Vos L; Bawden EG; Vogt TJ; Dietrich J; Zarbl R; Bootz F; Kristiansen G; Brossart P; Landsberg J; Dietrich D
Clin Epigenetics; 2019 Nov; 11(1):161. PubMed ID: 31747929
[TBL] [Abstract][Full Text] [Related]
11. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
12. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.
Placke JM; Soun C; Bottek J; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Pfeiffer C; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Zimmer L; Livingstone E; Becker JC; Lodde G; Sucker A; Griewank K; Horn S; Hadaschik E; Roesch A; Schadendorf D; Engel DR; Ugurel S
Front Oncol; 2021; 11():741993. PubMed ID: 34621681
[TBL] [Abstract][Full Text] [Related]
13. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Xiao Q; Nobre A; Piñeiro P; Berciano-Guerrero MÁ; Alba E; Cobo M; Lauschke VM; Barragán I
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31968651
[TBL] [Abstract][Full Text] [Related]
14. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
15. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
16. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Bolte LA; Lee KA; Björk JR; Leeming ER; Campmans-Kuijpers MJE; de Haan JJ; Vila AV; Maltez-Thomas A; Segata N; Board R; Harries M; Lorigan P; de Vries EGE; Nathan P; Fehrmann R; Bataille V; Spector TD; Hospers GAP; Weersma RK
JAMA Oncol; 2023 May; 9(5):705-709. PubMed ID: 36795408
[TBL] [Abstract][Full Text] [Related]
17. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
Gong X; Karchin R
Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy.
Zhao X; Wang Y; Jiang X; Mo B; Wang C; Tang M; Rong Y; Zhang G; Hu M; Cai H
BMC Cancer; 2023 Feb; 23(1):194. PubMed ID: 36855091
[TBL] [Abstract][Full Text] [Related]
19. Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy
Fan B; Zheng X; Wang Y; Hu X
Pathol Oncol Res; 2023; 29():1611117. PubMed ID: 37082269
[No Abstract] [Full Text] [Related]
20. Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators.
Byun HK; Chang JS; Jung M; Koom WS; Chung KY; Oh BH; Roh MR; Kim KH; Lee CK; Shin SJ
Front Oncol; 2021; 11():659754. PubMed ID: 34123816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
